Unlocking Lung Cancer Cell "Memories" Offers Promising Path for Enhanced Treatment

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have uncovered a novel approach to improve lung cancer treatment by tapping into the "memories" of cancer cells. The study, led by cancer biologist Tuomas Tammela, focused on lung adenocarcinoma, a prevalent form of non-small cell lung cancer often driven by mutations in the KRAS gene.

The traditional view of KRAS proteins as undruggable has evolved with the approval of KRAS inhibitors in recent years. However, these inhibitors are not universally effective, and cancer cells often develop resistance, leading to relapse. The MSK study, published in Cancer Discovery, sheds light on a potential strategy to enhance the efficacy of KRAS inhibition.

The research delves into lung biology, specifically the alveoli, where oxygen exchange occurs. Alveoli consist of two distinct cell types—alveolar type 1 (AT1) and alveolar type 2 (AT2). Lung cancer cells, originating from AT2 cells, can acquire "remembered" properties of AT1 cells, referred to as "AT1-like" cells.

The team's investigation revealed that after KRAS inhibitor treatment, the residual cancer cells were predominantly AT1-like cells, capable of reigniting uncontrolled cancer growth. Crucially, targeting and eliminating these AT1-like cells alongside KRAS inhibition significantly improved treatment response.

Dr. Tammela notes that while eliminating these cells in experimental models is feasible, translating this into clinical practice requires further research. The next step involves identifying unique surface proteins on AT1-like cells and developing therapeutics to selectively target and eliminate them.

In an era of advanced pharmacology, Dr. Tammela expresses optimism about the potential for engineered molecules to specifically target and eradicate these cells, drawing parallels with the success of therapies like CAR T cell therapy and antibody drug conjugates.